Dasatinib

Mucinous Adenocarcinoma of the Colon

National Cancer Institute (NCI)Small moleculeEarly Phase 1Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Mucinous Adenocarcinoma of the Colon cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM University of Southern California	Phase 3	BBB
Eloxatin John Hays	Phase 3	BB
Irinotecan Fox Chase Cancer Center	Phase 3	BB
Cetuximab National Cancer Institute (NCI)	Phase 2	BB
Edrecolomab National Cancer Institute (NCI)	Phase 3	B

View all 18 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant

BB

Indicative ·

70 / 100

chronic myeloid leukemiaDormant

BB

Indicative ·

68 / 100

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant

BB

Indicative ·

67 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.